Most of the treatments targeting cardiometabolic diseases such as diabetes and heart disease focus on reducing the effects rather than addressing the root causes.
That’s where Better Therapeutics steps in. The company has a platform for FDA-regulated, software-based, prescription digital therapeutics (PDTs) for treating diabetes, heart disease, and other cardiometabolic conditions at the source. The PDTs deliver a new kind of cognitive behavioral therapy that enable changes in neural pathways of the brain that leads to lasting behavioral change.
David Perry, chairman and co-founder of Better Therapeutics, spoke with Let’s Talk Medtech about the future of the company; how it can continue in its mission; and going public through a Special Purpose Acquisition Merger (SPAC).
The firm’s lead candidate, BT-001, is currently being studied for first-line treatment of type 2 diabetes. The product provides cognitive behavioral therapy modules to address education gaps in healthy and mindful eating, exercise, etc., and rewards healthy choices so participants can change the behaviors associated with their diseases, rather than take a drug to treat the symptoms. If the pivotal study is successful, they plan to file for marketing authorization from FDA and replicate this approach for other cardiometabolic conditions.